Ozempic and Alcohol Consumption Linked in New Study

A new study published today, October 17, 2025, indicates that medications like Ozempic, used for weight loss and diabetes management, may alter how the body processes alcohol.

Researchers found that glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide (Ozempic) and liraglutide (Wegovy), appear to reduce alcohol’s physiological and perceptual effects in individuals with obesity. The preliminary study, published in Scientific Reports, involved controlled alcohol consumption while monitoring participants’ physiological responses and subjective feelings. Participants on GLP-1 medications exhibited lower blood alcohol concentrations and reported feeling less intoxicated compared to those not on the drugs, even after consuming the same amount of alcohol.

The research team observed that GLP-1 agonists may speed up gastric emptying, potentially leading to faster alcohol absorption, but also influence brain responses to alcohol, diminishing its rewarding effects. This could have implications for individuals with a history of alcohol use disorder, as the altered perception of intoxication might affect drinking behaviors. Understanding the interplay between these medications and substance use is crucial, especially as the popularity of GLP-1 drugs continues to rise; learn more about the National Institute on Alcohol Abuse and Alcoholism.

These findings are preliminary and require further investigation to determine the long-term effects and broader applicability across different populations. Researchers emphasize the need for caution and continued monitoring of patients prescribed GLP-1 medications, particularly regarding potential interactions with alcohol. The impact of diabetes medications is an evolving area of study.

Health officials stated they will continue to analyze the data and provide updated guidance as more information becomes available.